Amneal Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Feb 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 27, 2026
AMRX$21.38+0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
| Years Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Cash flows from operating activities: | |||
| Net income (loss) | $127,933 | $(73,876) | $(48,722) |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | |||
| Depreciation and amortization | 223,572 | 236,191 | 229,400 |
| Unrealized foreign currency (gain) loss | (7,453) | 7,191 | (768) |
| Amortization of debt issuance costs and discount | 22,431 | 29,097 | 11,548 |
| Reclassification of cash flow hedge | 1,229 | (26,205) | (3,366) |
| Loss on refinancing | 31,365 | — | 40,805 |
| Intangible asset impairment charges | 22,784 | 920 | 66,932 |
| Change in fair value of contingent consideration | — | — | (14,497) |
| Stock-based compensation | 31,953 | 27,768 | 26,822 |
| Inventory provision | 85,962 | 96,558 | 74,686 |
| Other operating charges and credits, net | 4,732 | 1,523 | 9,923 |
| Changes in assets and liabilities: | |||
| Trade accounts receivable, net | (120,566) | (162,637) | 126,289 |
| Inventories | (87,026) | (130,530) | (126,182) |
| Prepaid expenses, other current assets and other assets | (19,163) | (959) | 37,814 |
| Related party receivables | (13) | 482 | (490) |
| Accounts payable, accrued expenses and other liabilities | 21,321 | 235,135 | (94,446) |
| Related party payables | 931 | 54,441 | 9,829 |
| Net cash provided by operating activities | 339,992 | 295,099 | 345,577 |
| Cash flows from investing activities: | |||
| Purchases of property, plant and equipment | (70,063) | (51,924) | (43,216) |
| Acquisition of intangible assets | (15,514) | (14,650) | (22,388) |
| Deposits for future acquisition of property, plant, and equipment | (28,780) | (8,416) | (3,585) |
| Proceeds from sale of property, plant, equipment and other | 2,094 | — | — |
| Proceeds from sale of subsidiary | — | 11,994 | — |
| Net cash used in investing activities | (112,263) | (62,996) | (69,189) |
| Cash flows from financing activities: | |||
| Proceeds from issuance of debt | 2,694,750 | — | 217,732 |
| Payments of principal on debt, revolving credit facility, financing leases and other | (2,811,508) | (188,918) | (414,080) |
| Payments of deferred financing, refinancing costs and debt extinguishment costs | (74,973) | (71) | (162,415) |
| Borrowings on revolving credit facility | 218,000 | 48,000 | 219,000 |
| Proceeds from exercise of stock options | 1,960 | 1,154 | 451 |
| Employee payroll tax withholding on restricted stock unit and performance stock unit vesting | (22,278) | (7,952) | (2,378) |
| Tax and other distributions to non-controlling interests | (43,848) | (19,804) | (70,883) |
| Payment of principal on notes payable - related party | — | (44,200) | — |
| Proceeds from alliance party | 6,367 | — | — |
| Net cash used in financing activities | (31,530) | (211,791) | (212,573) |
| Effect of foreign exchange rate on cash | (1,680) | (999) | 65 |
| Net increase in cash, cash equivalents, and restricted cash | 194,519 | 19,313 | 63,880 |
| Cash, cash equivalents, and restricted cash - beginning of period | 118,420 | 99,107 | 35,227 |
| Cash, cash equivalents, and restricted cash - end of period | $312,939 | $118,420 | $99,107 |
| Cash and cash equivalents - end of period | $282,029 | $110,552 | $91,542 |
| Restricted cash - end of period | 28,842 | 7,868 | 7,565 |
| Long-term restricted cash included in other assets - end of period | 2,068 | — | — |
| Cash, cash equivalents, and restricted cash - end of period | $312,939 | $118,420 | $99,107 |
Consolidated Statements of Cash Flows (continued)
| Years Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Supplemental disclosure of cash flow information: | |||
| Cash paid for interest | $197,848 | $263,518 | $192,806 |
| Cash paid, net for income taxes | $21,327 | $15,220 | $2,496 |
| Supplemental disclosure of non-cash investing and financing activity: | |||
| Payable for acquisition of product rights and licenses | $8,611 | $3,900 | $2,100 |
| Loan for land purchase - related party | $476 | $— | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.